2009
DOI: 10.1016/j.cyto.2009.07.387
|View full text |Cite
|
Sign up to set email alerts
|

The oral histone deacetylase inhibitor ITF2357 reduces cytokine production, cytokine activities and protects islet β-cells in vivo and in vitro

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

0
12
2
1

Year Published

2011
2011
2015
2015

Publication Types

Select...
5

Relationship

2
3

Authors

Journals

citations
Cited by 5 publications
(15 citation statements)
references
References 0 publications
0
12
2
1
Order By: Relevance
“…Thus, HDACi, such as givinostat, vorinostat and trichostatin A, reduce cytokineinduced beta cell toxicity and restore insulin secretion in vitro and in vivo [12,14,15,22,24]. However, all HDACi in current clinical use are non-selective, and it is not known which of the 11 HDACs produced by the beta cell [12] mediate the toxic effects of cytokines.…”
Section: Discussionmentioning
confidence: 99%
See 1 more Smart Citation
“…Thus, HDACi, such as givinostat, vorinostat and trichostatin A, reduce cytokineinduced beta cell toxicity and restore insulin secretion in vitro and in vivo [12,14,15,22,24]. However, all HDACi in current clinical use are non-selective, and it is not known which of the 11 HDACs produced by the beta cell [12] mediate the toxic effects of cytokines.…”
Section: Discussionmentioning
confidence: 99%
“…HDAC inhibition blocks cytokine-induced inducible nitric oxide synthase (iNOS) production [12,14,22]. We therefore investigated whether a deficiency in HDAC1, -2 or -3 affected cytokine-mediated iNos induction in INS-1 cells.…”
Section: Resultsmentioning
confidence: 99%
“…Effects on NO production, cytokine regulation (60) and reduced joint pain and inflammation documented in the SOJIA study (18) could be a rationale for HDACi use in osteoarthritis as well. Both types of joint diseases, RA and OA, induce severe joint bone damage with consequent clinically evident impairment of joint function.…”
Section: Influence On Bone Destructionmentioning
confidence: 99%
“…ITF2357 (generic givinostat) is a hydroxamic acid-containing, orally active inhibitor that is anti-inflammatory in the low nanomolar range, either in vitro or in vivo (9 -16). For example, in mice with inducible (17) or spontaneous (6) diabetes, a low dose of oral ITF2357 of 1.5 mg/kg/day protected the insulin-producing islets as well as the incidence of clinical diabetes. In a Phase I trial in healthy males, oral givinostat reduced the production of proinflammatory cytokines from whole blood cultures (18).…”
Section: Itf2357 (Generic Givinostat)mentioning
confidence: 99%